Monash IVF Group Ltd

As of June 30, 2024, Monash IVF Group Ltd carries a market capitalization of 298.07M, placing it among publicly traded companies globally. Its enterprise value stands at 378.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Monash IVF Group Ltd's next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2024, Monash IVF Group Ltd has 389.63M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 1.88, and the price-to-book ratio stands at 1.98.

As of June 30, 2024, Monash IVF Group Ltd trades at an EV/EBITDA multiple of 46.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 378.26M versus a market cap of 298.07M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, Monash IVF Group Ltd maintains a current ratio of 0.54, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.88, indicating elevated leverage, while an interest coverage ratio of 4.54 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2024, Monash IVF Group Ltd posted a negative return on equity (ROE) of -2.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.38, reflecting losses generated across the asset base. The company generates approximately 159,217.34 in revenue per employee across its workforce of 997.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.82 indicates how many times Monash IVF Group Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2024, Monash IVF Group Ltd recorded an income tax benefit of -2.93M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -6.63M and -4.06M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 2, 2026, Monash IVF Group Ltd's stock has gained approximately 9.85% over the past 52 weeks. The 50-day moving average sits at 0.40, while the 200-day moving average is 0.41.

Over the twelve months ended June 30, 2024, Monash IVF Group Ltd generated 158.74M in revenue and converted that into -4.06M in net income, yielding earnings per share of -0.01. EBITDA reached 8.07M, while operating income came in at -3.49M.

As of June 30, 2024, Monash IVF Group Ltd holds 7.06M in cash and equivalents against 84.28M in total debt, resulting in a net debt position of 30.03M. Total book value stands at 150.61M, with working capital of -34.16M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

Over the twelve months ended June 30, 2024, Monash IVF Group Ltd posted a gross margin of 89.57, reflecting its pricing power and cost economics. The operating margin of -2.20 and net profit margin of -2.56 provide insight into operational efficiency.

Over the twelve months ended June 30, 2024, Monash IVF Group Ltd paid dividends of 0.03 per share. The dividend payout ratio of -341.15 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.17, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Monash IVF Group Ltd shareholders.

Monash IVF Group Ltd's most recent stock split took place on April 30, 2020 with a 947:1014 split ratio.

As of June 30, 2024, Monash IVF Group Ltd has an Altman Z-Score of 0.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.